Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ADVM vs CVM: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ADVM Captures Overall Composite Edge (62.4 BUY vs 56.6 HOLD), While CVM Leads 3–2 on Growth & Valuation Pillars

ADVM Overall Winner 6-Pillar Tally: ADVM 2 – 3 CVM (1 Tie) Matrix Metrics: ADVM 4 – 4 CVM

As of Nov 16, 2026, Adverum Biotechnologies, Inc. (ADVM) captures the overall head-to-head institutional edge over Cel-Sci Corporation (CVM) on higher Unified Composite conviction (62.4/100 BUY vs. 56.6/100 HOLD) after splitting the core matrix 4–4 (led by Balance Sheet & Cash Flow, Options & Positioning), while CVM wins 3–2 across the 6-pillar growth and valuation breakdown. ADVM trades at $4.36 (N/M Forward P/E, 0.0% operating margin) versus CVM at $1.59 (23.0x Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: ADVM earns the overall head-to-head edge with a stronger Unified Composite Score (62.4/100 BUY vs. CVM 56.6/100 HOLD) and 1.04β · 17% Vol risk profile, whereas CVM leads top-line expansion (-62.7% YoY revenue growth, 1.12x PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: ADVM trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 57.0); meanwhile CVM is in a Breakdown options structure phase (RSI 57.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ADVM vs CVM
ADVM NASDAQ Head-to-Head Winner
Adverum Biotechnologies, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$4.36
+4.06% 1D
Market Cap $91.8M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.04β · 17% Vol
Unified Composite Score
62.4 / 100 BUY
Tech 60.0 Fund 57.0 Flow 62.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 57
RSI-14: 57.0 · SMA20: $4.21 · SMA50: $4.41
CVM NYSE American
Cel-Sci Corporation
Biological Products, (No Disgnostic Substances)
$1.59
+24.22% 1D
Market Cap $20.9M
TTM Revenue $28,558
Forward P/E 23.0x
Beta / 30D Vol 0.65β · 120% Vol
Unified Composite Score
56.6 / 100 HOLD
Tech 60.0 Fund 54.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 57
RSI-14: 57.1 · SMA20: $1.46 · SMA50: $1.66

6-Pillar Scorecard Institutional Category Breakdown (ADVM 2 – 3 CVM)

Columns: Metric · ADVM · CVM
1. Valuation Multiples CVM
Forward P/E N/M 23.0x
Trailing P/E N/M 23.0x
PEG Ratio N/M 1.12x
EV / Revenue N/M N/M
2. Growth & Scale CVM
Revenue Growth (YoY) -70.0% -62.7%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $28,558
Market Cap $91.8M $20.9M
3. Profitability & Quality CVM
Gross Margin N/A N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -417.8% -252.5%
4. Balance Sheet & Cash Flow ADVM
Cash Generation (TTM) N/A -$17M
Cash Flow Margin N/A N/A
Net Cash / Leverage -417.8% ROE $6.6M Net Debt (1.24x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ADVM
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile 30.2% (10th %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biological Products, (No Disgnostic Substances) Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ADVM (4) vs CVM (4)
Institutional Metric ADVM CVM Criterion Row Edge
Market Capitalization
Scale
$91.8M $20.9M Larger Scale ADVM
Trailing P/E Ratio
Valuation
N/M 23.0x Lower Multiple CVM
Forward P/E Ratio
Valuation
N/M 23.0x Lower Multiple CVM
Revenue Growth (YoY)
Growth
-70.0% -62.7% Higher Growth CVM
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-417.8% -252.5% Higher ROE CVM
52-Week Range Position
Momentum
55% ($2–$6) 10% ($1–$8) Stronger Trend ADVM
Beta / 30D Volatility
Risk Regime
1.04β · 17% Vol 0.65β · 120% Vol Lower Realized Risk ADVM
Unified Institutional Score
Composite Signal
62.4 / 100 (BUY) 56.6 / 100 (HOLD) Higher Composite ADVM
Trailing 12M Revenue (USD)
Operating Scale
N/A $28,558 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 1.12x PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (-417.8% ROE) -$17M ($6.6M Net Debt (1.24x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ADVM +12.12 pp
ADVM: +0.93% · CVM: -11.19%
3M Horizon ADVM +12.12 pp
ADVM: +0.93% · CVM: -11.19%
6M Horizon ADVM +12.12 pp
ADVM: +0.93% · CVM: -11.19%
1Y Horizon ADVM +12.12 pp
ADVM: +0.93% · CVM: -11.19%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ADVM vs CVM. Trailing 12-month operating profitability (ADVM 0.0% vs CVM 0.0%) and valuation multiples (ADVM N/M vs CVM 23.0x Forward P/E) are benchmarked directly in Pillar 4 below.

ADVM ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-417.8% · N/M
CVM ADR TTM Benchmark FX-Normalized USD
TTM Revenue$28,558
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-252.5% · 23.0x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ADVM UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 30.2%
IV Percentile 10th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ADVM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CVM BREAKDOWN
29d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CVM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ADVM Moat Profile Cyclical / Execution-Driven Positioning
Biological Products, (No Disgnostic Substances) Operator
Competes within the Biological Products, (No Disgnostic Substances) value chain with $91.8M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CVM Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $20.9M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ADVM vs CVM Key Questions & Quantitative Answers

As of Nov 16, 2026, Adverum Biotechnologies, Inc. (ADVM) captures the overall head-to-head institutional edge over Cel-Sci Corporation (CVM) on higher Unified Composite conviction (62.4/100 BUY vs. 56.6/100 HOLD) after splitting the core matrix 4–4 (led by Balance Sheet & Cash Flow, Options & Positioning), while CVM wins 3–2 across the 6-pillar growth and valuation breakdown. ADVM trades at $4.36 (N/M Forward P/E, 0.0% operating margin) versus CVM at $1.59 (23.0x Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: ADVM earns the overall head-to-head edge with a stronger Unified Composite Score (62.4/100 BUY vs. CVM 56.6/100 HOLD) and 1.04β · 17% Vol risk profile, whereas CVM leads top-line expansion (-62.7% YoY revenue growth, 1.12x PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: ADVM trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 57.0); meanwhile CVM is in a Breakdown options structure phase (RSI 57.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CVM leads the Growth & Scale pillar: ADVM posts -70.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with CVM at -62.7% YoY revenue growth and +0.0% YoY earnings growth on $28,558 TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, ADVM generates N/A in USD-normalized revenue versus $28,558 for CVM. In operating R&D and SG&A reinvestment, ADVM deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CVM.

CVM screens cheaper on headline valuation multiples. ADVM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas CVM trades at 23.0x Forward P/E, 23.0x Trailing P/E, 1.12x PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ADVM (-417.8% ROE) versus CVM (-252.5% ROE) capital efficiency.

In options market volatility and institutional positioning, ADVM carries 30.2% implied volatility (10th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.04β · 17% Vol realized risk). By comparison, CVM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.65β · 120% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.